Last update 11 May 2025

Fluorouracil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5-fluoro-1H-pyrimidine-2,4-dione, 5-Fluoropyrimidine-2,4-dione, 5-Fluorouracil
+ [36]
Target
Action
inhibitors
Mechanism
TYMS inhibitors(Thymidylate synthase inhibitors)
Login to view timeline

Structure/Sequence

Molecular FormulaC4H3FN2O2
InChIKeyGHASVSINZRGABV-UHFFFAOYSA-N
CAS Registry51-21-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Esophageal Carcinoma
Japan
25 Nov 2021
Intestinal Neoplasms
Japan
21 Sep 2018
Head and Neck Neoplasms
Japan
14 Feb 2005
Bowen's Disease
Australia
23 Aug 1991
Neoplasms
China
01 Jan 1981
Skin Neoplasms
Japan
26 Aug 1972
Actinic Keratosis
United States
29 Jul 1970
Advanced gastric carcinoma
Japan
24 Jul 1967
Endometrial Carcinoma
Japan
24 Jul 1967
Liver Cancer
Japan
24 Jul 1967
Lung Cancer
Japan
24 Jul 1967
Ovarian Cancer
Japan
24 Jul 1967
recurrent gastric cancer
Japan
24 Jul 1967
Stomach Cancer
Japan
24 Jul 1967
Uterine Cervical Cancer
Japan
24 Jul 1967
Breast Cancer
United States
25 Apr 1962
Colorectal Cancer
United States
25 Apr 1962
Pancreatic Cancer
United States
25 Apr 1962
stomach adenocarcinoma
United States
25 Apr 1962
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RAS/BRAF Wild Type Colorectal CancerPhase 3
Italy
12 Jun 2024
Cutaneous Squamous Cell CarcinomaPhase 3
United States
08 Jun 2023
Hypopharyngeal CarcinomaPhase 3
United States
08 Jun 2023
Squamous cell carcinoma of head and neck metastaticPhase 3
United States
08 Jun 2023
Squamous cell carcinoma of the hypopharynxPhase 3
United States
08 Jun 2023
Squamous Cell Carcinoma of the LarynxPhase 3
United States
08 Jun 2023
Squamous cell carcinoma of the oral cavityPhase 3
United States
08 Jun 2023
Adenocarcinoma of EsophagusPhase 3
United States
26 May 2020
Advanced Gastric AdenocarcinomaPhase 3
United States
26 May 2020
HER2 negative Gastroesophageal Junction AdenocarcinomaPhase 3
United States
26 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
72
Adjuvant RT+Nivolumab
(Single Modality De-escalation Arm (SDA))
yjzqbfkgrx = lwbnjqujlb tfmmdpslwo (ambqsnbyna, sjkkgjeatf - rwrjrilpdh)
-
06 May 2025
(Intermediate De-escalation Arm (IDA))
yjzqbfkgrx = vkmjbljfgq tfmmdpslwo (ambqsnbyna, telqehqpqa - sdsxiubunq)
Phase 2/3
635
Patient Observation
(Arm I (Blood Stored and Tested for ctDNA Later))
lnthgcjaci: P-Value = 0.98
-
27 Apr 2025
(Arm II (Blood Tested for ctDNA at Baseline))
Phase 2
28
impewxzbnv = rakfkuwtvc pxplkhhmvs (yzdssvgcyh, ekjmludkzv - jtujxmftcb)
-
18 Apr 2025
Phase 2
38
rkwlblqxmn = rzlatrguxd isnxxvkivm (wewsmwwnfv, dhbmijuwwy - vbanwhmfly)
-
25 Feb 2025
Not Applicable
Muscle Invasive Bladder Carcinoma
Neoadjuvant | Adjuvant
29
Durvalumab + Chemoradiotherapy
cihqjolyni(vtlcqdpysb) = 6 related to trial treatment kvqpvghesp (xlvkuatoyi )
Positive
13 Feb 2025
Not Applicable
23
txeperyuxy(globhstkys) = guwqdmcoyf unqztgkkot (tkqpvfzagr )
Positive
23 Jan 2025
Phase 2
54
Neoadjuvant FLOT therapy
pgtliutqld(zcfudgajvg) = vzakuhjedy ieclakfccs (dpunaunqmo, 29.8 - 57.7)
Positive
23 Jan 2025
Not Applicable
CA 19-9
52
(Effective Group)
ffcmhrwqti(pylbjwekra) = esufjlsmcg adxvpkbcgw (shhqlottwy )
Positive
23 Jan 2025
Phase 1
14
Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B)
letgjywrbp(itxgxempyi) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism nafmjvlugv (xgcjapgprd )
Positive
23 Jan 2025
Not Applicable
-
Lenvatinib plus FOLFOX-HAIC
clygftaoqt(ypjeymcfcl) = Grade 3-4 adverse events, including nausea, vomiting, diarrhea, thrombocytopenia, and neutropenia, were more prevalent in the lenvaHAIC group uydhxuecws (kcnbqxfiyf )
Positive
23 Jan 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free